GE Medical Systems has received a Food and Drug Administration warning letter regarding deficient procedures at the manufacturing facility in Buc, France, where the vendor's Senographe 2000D full-field digital mammography system is manufactured.
In an April 10 letter (see link below), the FDA's Center for Devices and Radiological Health said a December inspection of the facility revealed that "the methods used in, or the facilities or controls used for the manufacturing, packing, storage, or installation, are not in conformance with the Quality System regulations for Medical Device regulations."
The letter goes on to cite several deficiencies, along with an evaluation of GE's previous communication with the agency. The vendor has 15 business days within receipt of the correspondence to notify the CDRH of the specific steps it has taken, or will take, to correct the violations, according to the correspondence.
GE is in the process of responding to the letter, which requests further documentation of procedures, spokesperson Patrick Jarvis told AuntMinnie.com.
"We're confident that we can address any of the remaining issues that are in the letter, and don't anticipate future action from the FDA," he said.
By AuntMinnie.com staff writersApril 25, 2001
Links
April 10 letter from CDRH (PDF format)
Download Adobe Acrobat (PDF) reader
Related Reading
Full-field digital mammography offers higher sensitivity, lower doses, March 28, 2001
Film-screen mammography remains gold standard, IOM says, March 8, 2001
Full-field digital mammography is finally ready for prime time, November 16, 2000
Copyright © 2001 AuntMinnie.com











![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)






